Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan

NEW YORK, July 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan
http://www.reportlinker.com/p0934893/Generic-and-innovative-drugs-market-in-CIS-countries-2013-Russia-Ukraine-and-Kazakhstan.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Keep current with the changing CIS generic and innovative drug segments.
Survey conditions and track market development in Russian Ukraine and Kazakhstan to 2015.

Generic and innovative drug segments in CIS countries have played a huge role in supporting the pharmaceutical industry. Meanwhile, the effects of programmes such as Russia's Pharma 2020, Kazakhstan's GMP initiative and Ukraine's updated reimbursement structure are visible in the marketplace.
How will issues like these influence market development in the next few years? How will they change pricing structures and reimbursement schemes? What are the rules regarding data exclusivity periods and drug patent viability?
Stay informed with regard to these topics and many more by reviewing Generic and innovative drugs market in CIS countries 2013, Russia, Ukraine and Kazakhstan, Development forecasts for 2013-2015. This authoritative report is a single and complete source of market data, analysis and forecasts, combined to serve the needs of professionals with interests in the market.

This PMR publication includes all relevant data concerning the size and value of the generic and innovative drugs markets in Russia, Ukraine and Kazakhstan. The document enables users to perform comparative analysis of market conditions in each country quickly and simply. It provides market share data for these drug segments in each of the three countries, highlights the top selling products, and profiles the companies that lead the region in production and sale of generic and innovative preparations. The report takes a look at the future of the markets, predicting the effects of trends and regulatory actions on growth and development in carefully constructed forecasts that span the period 2013-2015.

Each country is closely examined in terms of its regulatory environment. Reimbursement structures and listing procedures are defined, along with drug patent regulations and data exclusivity periods. Pricing criteria, including VAT rates on medicines and price mark ups and the variations in rules from country to country are explained. PMR has collected information from a wide variety of reliable sources and combined it to create a single convenient and easy to use document that enables industry professionals to perform critical tasks with accuracy and confidence in their business success.

Whether investigating CIS data on the generic and innovative drug market while considering possible entry, creating or expanding a portfolio of products or providing financial or consulting services to businesses engaged in the CIS markets, Generic and innovative drugs market in CIS countries 2013, Development forecasts for 2013-2015 provides solid informational support. PMR clients consult the report when monitoring changing reimbursement lists and procedures, preparing a corporate growth strategy, locating investments, preparing corporate reports and keeping up with regulatory changes in the CIS region.

Subjects studied within this report include:
• Size data of each market segment in the CIS region: generic drugs and innovative drugs - for each year from 2009 to 2015.
• Market share of each of the two segments in Russia, Ukraine and Kazakhstan
• Regulations in each country that govern pricing and reimbursement
• In-depth market development forecasts for the period 2013-2015 – for each segment in each country
• Applicable VAT rates for various types of generic and innovative medicines
• Price mark ups for applicable medicines (average and official)
• Reimbursement structures in each of the CIS countries
• Attributes of commonly used systems for reimbursement for generic and innovative drugs in CIS countries
• Changing drug reimbursement lists: the latest adjustments and expected future modifications
• Impact of reimbursement policy changes on the overall generic and innovative markets
• Periods of data exclusivity and patent expirations for generic and innovative drugs in CIS countries
• Innovative and generic medicines generating the highest sales
• Profiles of the most prolific companies manufacturing generic and innovative drugs in each country and across the region
• The counterfeit market – shares of overall sales and regulations in place in each of the covered countries: Russia, Ukraine and Kazakhstan.

These convenient features make the report useful in everyday operations:

• Comparative analysis of vital data and current market conditions in each of the CIS countries
• Analysis of generic/innovative drug pricing policies and reimbursement schemes in each CIS country
• Complete, insightful forecasts for the market to 2015
• Well-researched industry intelligence obtained from a wide range of sources and assembled into one reasonably priced resource.

Learn about specific issues and their impact on the market:

• Progress of the Ukrainian reimbursement structure, initiated in 2012
• Russia's Pharma 2020 programme and its regulations on foreign generic/innovative drug producers aimed at strengthening the domestic pharmaceutical industry
• Progress on the integration of GMP (Good Manufacturing Practice) in Kazakhstan.

This report answers your questions about the generic/innovative drug market in CIS, including:

• What are the specific values of the market for generic/innovative drugs during the period 2009-2015?
• How large are these market segments in Russia? Ukraine? Kazakhstan?
• Which countries will experience the quickest rates of growth in the generic/innovative drug sector between 2013-2015?
• How do consumers and physicians view generic/innovative drugs in CIS countries?
• How are the prices of both reimbursed and non-reimbursed generic/innovative drugs regulated in CIS countries?
• What are the specific reimbursement processes in place in each CIS country?
• What changes are in store for these drug markets and for reimbursement systems in the next few years?
• Which recent regulatory adjustments have altered market conditions?
• What are the latest additions and eliminations from the reimbursement lists of each highlighted country?
• How long are drug patents viable under the laws of each CIS country?
• What are the data exclusivity periods for generic/innovative drug products in CIS countries?
• Which generic/innovative drugs post the highest sales in this region?
• Which companies manufacture the greatest quantities of generic and innovative drugs within the CIS region? In each specific country?

Selected companies analysed in this report:

AstraZeneca, Bayer, Berlin-Chemie/Menarini, Dr. Reddy's, Egis, Farmak, Gedeon Richter, GSK, Krka, Novartis, Nycomed/Takeda, Pfizer, Pharmstandard, Ranbaxy/Daiichi Sankyo, Roche, Sanofi, Servier, Stada, Teva, Veropharm.

This report provides the specific, reliable market information required by:

• Companies engaged in the production and distribution of generic/innovative drugs and treatments in CIS countries
• Businesses building a strategy for entry into this market
• Financial service providers engaged in the banking, investment, brokerage and private equity sectors
• Business consulting, market research and analysis service providers
• Organisations engaged in the promotion of pharma-related industry, trade and commerce in CIS countries
• Research, academic and governmental entities with interests in this market.

Convenient availability of data and analysis aids in:

• Setup of operations in the generic and/or innovative drug segments in the CIS region or specific countries
• Assembling a diverse product portfolio
• Comparing the regulatory frameworks of CIS countries with regard to generic and/or innovative drugs and treatments
• Keeping current with changing drug lists – reimbursement and vital and essential – in each CIS country
• Assessing the possibilities for growth in these market segments across the CIS region and in specific countries
• Compiling forecasts for market conditions in the innovative and generic drug segments in CIS countries for the coming years.

Extract from this report

• If the CIS region is taken into consideration, Russia accounted for almost 77% in terms of value of the generic drug subgroup in 2012. The share was close to 80% in 2011, but there was a reduction in the figure after the lowest rate of growth of the generic market among the CIS countries analysed.
• In 2012 growth on the generic drug market in Russia fell short of that of previous years, because of the limited growth in disposable income in 2011-2012, along with low inflation and a slowdown of the overall economy.

I. Methodology p. 13

II. Executive summary p. 19

III. Characteristics of generic and innovative drug markets in Russia, Ukraine and Kazakhstan p. 25
• Comparative analysis p. 25
• Share of Russia, Ukraine and Kazakhstan as a proportion of generic and innovative drug subgroups in CIS p. 25
• Share of generic and innovative medicines as a proportion of the pharmaceutical market p. 26
• CAGR for generic and innovative medicines for 2013-2015 p. 27
• Market value of generic and innovative medicines in CIS between 2011 and 2015 p. 28
• Reimbursement and pricing policies p. 29
• Key manufacturers and best-selling medicines p. 30
• Drug patent expiry and data exclusivity periods p. 30
• GMP standards p. 30
• Russia p. 31
• Main past trends and events on generic and innovative drug market 31
• Main anticipated trends and events on generic and innovative drug market p. 34
• Share of pharmaceutical market p. 38
• Market value and forecasts 2009-2015 p. 40
• Ukraine p. 42
• Main past trends and events on generic and innovative drug market p. 42
• Main anticipated trends and events on generic and innovative drug market p. 45
• Share of pharmaceutical market p. 48
• Market value and forecasts 2009-2015 p. 49
• Kazakhstan p. 53
• Main trends and events on generic and innovative drug market p. 53
• Share of pharmaceutical market p. 54
• Market value and forecasts 2009-2015 p. 56

IV. Drug patent expiry and data exclusivity periods in CIS p. 59
• Russia p. 59
• Drug patent expiry p. 59
• Data exclusivity periods p. 60
• Ukraine p. 60
• Drug patent expiry p. 60
• Data exclusivity periods p. 60
• Kazakhstan p. 61
• Drug patent expiry p. 61
• Data exclusivity periods p. 61

V. Best-selling drugs in CIS countries p. 63
• Russia p. 63
• Pharmacy subgroup p. 63
• Hospital subgroup p. 64
• Reimbursement subgroup p. 65
• Ukraine p. 65
• Pharmacy subgroup p. 65
• Hospital subgroup p. 66
• Kazakhstan p. 66
• Pharmacy subgroup p. 66
• Hospital subgroup p. 67

VI. Counterfeit medicines in CIS p. 69
• Russia p. 69
• Market size p. 69
• Categories of counterfeit drugs p. 70
• Legal environment p. 71
• Ukraine p. 71
• Market size p. 71
• Categories of counterfeit drugs p. 72
• Legal environment p. 72
• Kazakhstan p. 73
• Market size p. 73
• Categories of counterfeit drugs p. 73
• Legal environment p. 73

VII. Reimbursement and pricing policies in Russia, Ukraine and Kazakhstan p. 75
• Russia p. 75
• Pricing policy p. 75
• VAT p. 75
• Non-essential drugs p. 75
• Vital and essential drugs p. 76
• Drugs on the hospital market p. 79
• Reimbursement policies p. 80
• Reimbursement system p. 80
• Market structure p. 81
• Top INN names p. 81
• Top ATC categories p. 82
• Share of ZHNVLP and non-ZHNVLP drugs p. 83
• Reimbursement process p. 84
• Latest changes to ZHNVLP lists p. 86
• Rare diseases p. 87
• Reimbursement spending p. 88
• Seven disease categories programme (VZN or 7 categories) p. 88
• Ukraine p. 89
• Pricing policy p. 89
• VAT p. 89
• Drugs on the pharmacy market p. 89
• Essential medicines and minimum mandatory range p. 92
• Market structure p. 92
• Prices p. 93
• Markups p. 94
• Drugs on the hospital market p. 95
• Market structure p. 95
• Prices p. 95
• Reimbursement policies p. 97
• Reimbursement system p. 97
• Latest changes to reimbursed drug lists p. 98
• Kazakhstan p. 98
• Pricing policy p. 98
• VAT p. 98
• Drugs on the pharmacy market p. 98
• Drugs on the hospital market p. 99
• Essential medicines p. 100
• Reimbursement policy p. 100
• Reimbursement system p. 100
• Reimbursement process p. 101
• Latest changes to the reimbursed drug lists p. 101

VIII. Key manufacturers in CIS countries p. 103
• Key players in Russia p. 103
• Total market p. 103
• Pharmacy subgroup p. 104
• Reimbursement subgroup p. 104
• Hospital subgroup p. 105
• Oncology subgroup p. 106
• Major events and trends associated with generic and innovative manufacturers p. 107
• Investments in production p. 107
• Product development p. 110
• Acquisition of companies/companies' portfolios p. 111
• Key players in Ukraine p. 112
• Pharmacy subgroup p. 112
• Hospital subgroup p. 113
• Major events and trends associated with generic and innovative manufacturers p. 114
• Investments in production p. 114
• Acquisition of companies/companies' portfolios p. 114
• Key players in Kazakhstan p. 115
• Pharmacy subgroup p. 115
• Hospital subgroup p. 116
• Major events and trends associated with generic and innovative manufacturers p. 116
• Acquisition of companies/companies' portfolios p. 116
• Investments in production p. 117
• Profiles of selected leading innovative drug manufacturers p. 118
• Profiles of selected leading generic drug manufacturers p. 137

IX. List of graphs p. 159

X. List of tables p. 163

XI. About PMR p. 167

List of graphs

1. Value (€ bn) and y-o-y change (%) of the CIS generic drug market, 2011-2015 20
2. Value (€ bn) and y-o-y change (%) of the CIS innovative drug market, 2011-2015 20
3. Share of specific countries as a proportion of the generic drug market in CIS countries (%), by value, 2011-2012 25
4. Share of specific countries as a proportion of the innovative drug market in CIS countries (%), by value, 2011-2012 26
5. Share of generic drugs as a proportion of the pharmaceutical markets in CIS countries (%), by value, 2012 26
6. Share of innovative drugs as a proportion of the pharmaceutical markets in CIS countries (%), by value, 2012 27
7. CAGR for innovative and generic medicines in CIS countries analysed (%), 2013-2015 27
8. Value (€ bn) and y-o-y change (%) of the CIS generic drug market, 2011-2015 28
9. Value (€ bn) and y-o-y change (%) of the CIS innovative drug market, 2011-2015 28
10. Number of clinical trials approved in Russia (%), by type, 2012 31
11. Number of clinical trials approved in Russia (%), by phase, 2012 32
12. Shares of generic and innovative drugs as a proportion of the pharmacy market in Russia (%), by value, 2012 39
13. Shares of generic and innovative drugs as a proportion of the hospital market in Russia (%), by value, 2012 39
14. Shares of generic and innovative drugs as a proportion of the pharmacy and hospital market in Russia (%), by value, 2012 40
15. Value (RUB bn) and y-o-y change (%) of the Russian generic drug market, 2011-2015 41
16. Value (RUB bn) and y-o-y change (%) of the Russian innovative drug market, 2011-2015 41
17. Shares of generic and innovative drugs as a proportion of the pharmacy market in Ukraine (%), by value, 2012 48
18. Shares of generic and innovative drugs as a proportion of the hospital market in Ukraine (%), by value, 2012 48
19. Shares of generic and innovative drugs as a proportion of the pharmacy and hospital market in Ukraine (%), by value, 2012 49
20. Change in sales volume of generic and innovative medicines in Ukraine (%, y-o-y), pharmacy market, 2011-2012 49
21. Change in sales value of generic and innovative medicines in Ukraine (%, y-o-y), pharmacy market, 2011-2012 50
22. Value (UAH bn) and y-o-y change (%) of the Ukrainian generic drug market, 2009-2015 51
23. Value (UAH bn) and y-o-y change (%) of the Ukrainian innovative drug market, 2009-2015 52
24. Shares of generic and innovative drugs as a proportion of the pharmacy market in Ukraine (%), by value, 2012 55
25. Shares of generic and innovative drugs as a proportion of the hospital market in Ukraine (%), by value, 2012 55
26. Shares of generic and innovative drugs as a proportion of the pharmacy and hospital market in Ukraine (%), by value, 2012 55
27. Value (KZT bn) and y-o-y change (%) of the Kazakh generic drug market, 2011-2015 56
28. Value (KZT bn) and y-o-y change (%) of the Kazakh innovative drug market, 2011-2015 57
29. Breakdown of prices of vital and essential drugs in Russia, 2013 77
30. Drug price breakdown in the ZHNVLP subgroup in Russia, by value, H1 2011-H1 2012 78
31. Drug price breakdown in the ZHNVLP subgroup in Russia, by volume, H1 2011-H1 2012 79
32. Average price per packet of medicine in the hospital drug subgroup in Russia ($) and change (%), 2010 – Q1-Q3 2012 80
33. Drug supply state funding system in Russia, 2013 80
34. Share of ZHNVLP and non-ZHNVLP as a proportion of the Russian pharmaceutical market (%), by value, 2010-2012 83
35. Share of ZHNVLP and non-ZHNVLP as a proportion of specific subgroups of the Russian pharmaceutical market (%), by value, 2012 83
36. Drug reimbursement process in Russia – placing of drugs on the DLO list, 2013 84
37. Drug reimbursement process in Russia – drug provision within the DLO subgroup, 2013 85
38. Number and y-o-y change (%) of INNs on the ZHNVLP list in Russia, 2009-2013 86
39. Origin of medicines on the ZHNVLP lists in Russia (%), 2012-2013 86
40. Value (RUB bn) and volume (million packets) of the DLO subgroup in Russia, 2010-2012 88
41. Formula for calculating the price of imported medicines which enter wholesale circulation in Ukraine, 2013 91
42. Average pharmacy margins on medicines in Ukraine (%), 2010-2012 91
43. Average markups for medicines on List of Essential Medicines and in mandatory minimum range in Ukraine (%), January-August 2010-2012 94
44. Breakdown of the Ukrainian hospital market by drug price (%), by volume, H1 2012 95
45. Breakdown of the Ukrainian hospital market by drug price (%), by value, H1 2012 96
46. Average price per packet of medicine in Ukraine (UAH), hospital market, imported and domestic drugs, Q1-Q3 2010 – 2012 96
47. Average price per packet of medicine in pharmacy subgroup in Kazakhstan ($) and y-o-y change (%), 2010 – Q1-Q3 2012 98
48. Breakdown of the pharmacy market of Kazakhstan by drug price (%), by value, Q1 2012 99
49. Average price per packet of medicine in hospital subgroup in Kazakhstan ($) and y-o-y change (%), 2010 – Q1-Q3 2012 100
50. Dr. Reddy's sales revenues (€ m) and y-o-y change (%) in Russia, FY 2005 – Q1-Q3 FY 2013 138
51. Share of individual countries as a proportion of Egis' revenues in the CIS region (%), 2009/2010-Q1 2012/2013 140
52. Farmak net sales revenue ($ m) and y-o-y change (%), 2009-2013 141
53. Share of individual countries as a proportion of Gedeon Richter female healthcare product sales value in CIS countries (%), 2012 143
54. Breakdown of Pharmstandard sales (%), by category 2012 147
55. Ranbaxy sales in Russia and Ukraine (€ m) and y-o-y change (%), 2008-2012 151

List of tables

1. Annual average exchange rates used in this report (€ to national currency), 2010-2012 15
2. Comparison of VAT rates, drug price controls, reimbursement solutions, patent protection and future developments for reimbursement system in CIS countries analysed, 2013 29
3. Drug patent expiry and data exclusivity periods in CIS countries analysed in comparison with EU, 2013 30
4. Expected results of the Strategy for supplying the Russian population with medications for the period until 2025, essential medicines supply, 2012-2025 37
5. Expected results of the Strategy for supplying the Russian population with medications for the period until 2025, mortality rates, 2012-2020 37
6. Basic sales indicators for hypertensive medicines included in the pilot reimbursement project in Ukraine, 2011-2012 44
7. Top 10 best-selling innovative and generic drugs in Russia, by value, pharmacy subgroup, 2012 64
8. Top 10 best-selling innovative and generic drugs in Russia, by value, hospital subgroup, Q1-Q3 2012 64
9. Top 10 best-selling innovative and generic drugs in Russia, by value, reimbursement subgroup, Q1-Q3 2012 65
10. Top 10 best-selling innovative and generic drugs in Ukraine, by value, pharmacy market 2012 65
11. Top 20 best-selling generic and innovative drugs in Ukraine, by value, hospital subgroup, 2012 66
12. Top 10 best-selling generic and innovative drugs in Kazakhstan, by value, pharmacy subgroup, Q1-Q3 2012 67
13. Top 10 best-selling generic and innovative drugs in Kazakhstan, by value, hospital subgroup, Q1-Q3 2012 67
14. Number of drug brand names and drug series of counterfeit medicines withdrawn from the Russian pharmaceutical market, 2005 – Q1-Q3 2012 70
15. Top 10 INNs in the DLO subgroup in Russia, by value, Q1-Q3 2012 81
16. Top 20 INNs of the ZHNVLP subgroup in Russia, by value, Q1 2012 81
17. Top 20 INNs of the ZHNVLP subgroup in Russia, by volume, Q1 2012 82
18. Top 10 ATC categories in the DLO subgroup in Russia, by value, Q1-Q3 2012 82
19. List of life-threatening and chronic progressive rare (orphan) diseases in Russia, 2013 87
20. Breakdown of the Ukrainian pharmacy market by drug price, by volume, 2012 90
21. Breakdown of the Ukrainian pharmacy market by drug price, by value, 2012 90
22. Average price per packet of medicine in Ukraine (UAH), pharmacy market, imported and domestic drugs, 2012 90
23. Breakdown of the Ukrainian pharmacy market by imported and domestic drugs, by price range, 2010-2012 90
24. Share of medicines on List of Essential Medicines and in mandatory minimum range as a proportion of the Ukrainian pharmacy market (%), January-August 2010-2012 92
25. Share of imported and local medicines on List of Essential Medicines and in mandatory minimum range in Ukraine (%), pharmacy market, January-August 2010-2012 93
26. Market share of medicines on List of Essential Medicines and in mandatory minimum range in Ukraine by value and volume (%), by price range, January-August 2012 93
27. Market share of imported and domestic medicines on List of Essential Medicines and in mandatory minimum range in Ukraine, by value and volume (%), by price range, January-August 2012 93
28. Maximum retail markups for medicines on List of Essential Medicines and in mandatory minimum range in Ukraine (%), 2013 94
29. Average markups for medicines on List of Essential Medicines and in mandatory minimum range in Ukraine, by price range (%), January-August 2010-2012 95
30. Top 10 generic and innovative pharmaceutical domestic manufacturers in Russia, by value, Q1-Q3 2012 103
31. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, pharmacy subgroup, 2012 104
32. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, reimbursement subgroup, Q1-Q3 2012 104
33. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, hospital subgroup, Q1-Q3 2012 105
34. Top 10 generic and innovative domestic pharmaceutical manufacturers in Russia, by value, hospital subgroup, Q1-Q3 2012 105
35. Top 10 generic and innovative domestic pharmaceutical manufacturers in Russia, by value, oncology subgroup, Q1-Q3 2012 106
36. Top 10 generic and innovative domestic pharmaceutical manufacturers in Russia, by volume, oncology subgroup, Q1-Q3 2012 106
37. Selected completed investments in pharmaceutical production in Russia, 2011-Q1 2013 107
38. Selected planned investments in pharmaceutical production in Russia, 2013-2017 108-109
39. Selected agreements pertaining to new product development in Russia, 2012-Q1 2013 110
40. Selected pharmaceutical companies acquired in Russia, 2012-Q1 2013 111
41. Top generic pharmaceutical manufacturers in Ukraine, by value, pharmacy subgroup, 2012 112
42. Top innovative pharmaceutical manufacturers in Ukraine, by value, pharmacy subgroup, 2012 112
43. Top generic pharmaceutical manufacturers in Ukraine, by value, hospital subgroup, Q1-Q3 2012 113
44. Top innovative pharmaceutical manufacturers in Ukraine, by value, hospital subgroup, Q1-Q3 2012 113
45. Acquisition of selected pharmaceutical companies in Ukraine, 2012-Q1 2013 115
46. Top 10 generic and innovative pharmaceutical manufacturers in Kazakhstan, by value, pharmacy subgroup, Q1-Q3 2012 115
47. Top 10 generic and innovative pharmaceutical manufacturers in Kazakhstan, by value, hospital subgroup, Q1-Q3 2012 116
48. Acquisition of selected pharmaceutical companies in Kazakhstan, 2012-Q1 2013 116
49. Selected planned investments in pharmaceutical production in Kazakhstan, 2013-2016 117
50. Bayer pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012 118
51. Bayer's clinical trials carried out in CIS countries analysed, March 2013 119
52. GSK pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012 119
53. GlaxoSmithKline's clinical trials carried out in CIS countries analysed, March 2013 121
54. Novartis pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012 122
55. Novartis' clinical trials carried out in CIS countries analysed, March 2013 123
56. Nycomed/Takeda pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012 124
57. Takeda, selected business partners and their products in Takeda's portfolio in CIS countries, 2013 125-126
58. Takeda clinical trials carried out in CIS countries analysed, March 2013 127
59. Pfizer pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012 128
60. Pfizer's clinical trials carried out in CIS countries analysed, March 2013 129
61. Roche's clinical trials carried out in CIS countries analysed, March 2013 131
62. Sanofi pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012 132
63. Sanofi's clinical trials carried out in CIS countries analysed, March 2013 135
64. Servier pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012 135
65. Berlin-Chemie/Menarini pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012 137
66. Sales value ($ m) and growth (%) of selected Dr. Reddy's brands in Russia, FY 2011-2012 139
67. Egis sales in individual CIS countries (€ m) and y-o-y change (%), 2008/2009-Q1 2012/2013 139
68. Gedeon Richter sales in individual CIS countries (€ m) and y-o-y change (%), 2007-2012 142
69. Products launched by Gedeon Richter in CIS countries, 2012 143
70. Krka sales in selected CIS countries (€ m) and y-o-y change (%), 2007-2012 145
71. Selected products launched by Krka in CIS countries, Q1-Q3 2012 145
72. Pharmstandard sales in individual CIS countries (€ m) and y-o-y change (%), 2009-2012 147
73. Pharmstandard's best-selling own Rx generic and innovative drugs in the CIS, by value, 2012 149
74. New products due to be introduced on the market by Pharmstandard, 2013 150
75. New generics products due to be introduced on the market by Pharmstandard, 2013 150
76. Ranbaxy/Daiichi's clinical trials carried out in CIS countries analysed, March 2013 153
77. Stada sales of generic and branded products in Russia (€ m) and y-o-y change (%), 2008 – Q1-Q3 2012 153
78. Stada sales of generic and branded products in Ukraine (€ m) and y-o-y change (%), 2008 – Q1-Q3 2012 153
79. Stada sales of generic and branded products in Kazakhstan (€ m) and y-o-y change (%), 2008 – Q1-Q3 2012 154
80. Teva sales in individual CIS countries (€ m) and y-o-y change (%), 2010-2012 156
81. Teva's clinical trials carried out in CIS countries analysed, March 2013 157

To order this report:
Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan

Contact Clare: clare@reportlinker.com  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker